TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9554567
Drug: rhIGF‐1 (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIGF‐1 (80 µg/kg/day) + rhGH (50 µg/kg/day)
Study: 7802322
Drug: Buccal prosidol
Normalized name: Prosol
DrugBank: Proline (DB00172)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buccal prosidol tablets
Study: 3197580
Drug: Cisapride (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (10 mg intravenous bolus injection)
Study: 31357997
Drug: Mass Testing
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass Testing and Treatment (MTaT) delivered by community health volunteers (CHVs) three times a year for 2 years
Study: 21761706
Drug: Sublingual administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual administration of allergen (SLIT)
Study: 21761706
Drug: Nasal spray
Normalized name: Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray of budesonide (Control)
Study: 19258920
Drug: Motavizumab 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motavizumab 15 mg/kg
Study: 16961676
Drug: Drug only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug only (orlistat)
Study: 16961676
Drug: Drug +
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug + brief counselling
Study: 15532817
Drug: Cimetidine administered
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine administered at an early stage after bowel surgery while receiving parenteral nutrition
Study: 11683207
Drug: Gonadotropin‐releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotropin‐releasing hormone agonist (GnRHa) alone or in combination with growth hormone (GH) for 3 years
Study: 9804577
Drug: High-protein diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein diet (HP; 1.8 g . kg‐1 . day‐1)
Study: 9804577
Drug: Low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diet (LP; 0.7 g . kg‐1 . day‐1)
Study: 7933348
Drug: Penicillin V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin V (500 mg twice a day)
Study: 3415422
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of fluphenazine decanoate (average, 25 mg every two weeks)
Study: 3415422
Drug: Minimal dose
Normalized name: Centipeda minima whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal dose of fluphenazine decanoate (average, 3.8 mg every two weeks)
Study: 30768663
Drug: Internal hex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internal hex and convergent transmucosal collar implants
Study: 30768663
Drug: Supracrestally placed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supracrestally placed implants
Study: 29941500
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine followed by metformin for 3 months and then metformin for 9 months
Study: 29941500
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine followed by metformin
Study: 17693905
Drug: Inhaled steroid,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled steroid, Budesonide (0.25 mg/2 mL)
Study: 17693905
Drug: Inhaled placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled placebo (2 mL of inhaled 0.9% saline)
Study: 12040440
Drug: BFM-oriented therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: BFM-oriented therapy without cranial irradiation
Study: 12040440
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of L-asparaginase (HD-L-ASP) during maintenance treatment
Study: 12040440
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of intravenous 6-mercaptopurine (HD-6MP) during protocol M
Study: 31401909
Drug: Problem-solving therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-solving therapy (PST-PC)
Study: 7488410
Drug: EPI 120
Normalized name: 8-epi-cyanocobalamin
DrugBank: 8-epi-Cyanocobalamin (DB14092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPI 120 mg/m2 every 3 weeks
Study: 7488410
Drug: EPI 120
Normalized name: 8-epi-cyanocobalamin
DrugBank: 8-epi-Cyanocobalamin (DB14092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPI 120 mg/m2 + LND (150 mg on day 1, 300 mg on day 2, 450 mg on days 3-5)
Study: 2139996
Drug: Verapamil hydrochloride
Normalized name: Verapamil Hydrochloride
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil hydrochloride aerosol therapy (10 mg/day on days 10, 12, 14, 16, 18, 20, 22)
Study: 7377255
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of estradiol valerate
Study: 31464912
Drug: SOCG (SOCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOCG (SOCG tablet)
Study: 24194293
Drug: Nelfinavir (NFV)
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nelfinavir (NFV) 1,250 mg bid concurrent with temozolomide (TMZ) 150-200 mg/m(2) and radiotherapy (6,000 cGy)
Study: 24194293
Drug: Nelfinavir (NFV)
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nelfinavir (NFV) 625 mg bid concurrent with temozolomide (TMZ) and radiotherapy
Study: 20810596
Drug: Second-generation antipsychotics
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation antipsychotics plus cognitive-behavioral therapy
Study: 20810596
Drug: Second-generation antipsychotics
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation antipsychotics alone
Study: 15250203
Drug: Chuankezhi injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chuankezhi injection
Study: 15250203
Drug: Ginkgo injection
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo injection
Study: 12431243
Drug: Oral taurine
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral taurine (1000 mg d(-1))
Study: 8137333
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation with 26 vitamins and minerals for 6 years
Study: 477258
Drug: Intravenous sodium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sodium chloride (50 mmol three times daily for 3 days)
Study: 477258
Drug: Intravenous sodium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sodium chloride (50 mmol in 50 ml over 22 min)
Study: 21304064
Drug: Lean subjects
Normalized name: Lophophytum leandrii extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lean subjects (L)
Study: 15262693
Drug: MT‐1 (0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: MT‐1 (0.08 mg/kg per day subcutaneously) with UV‐B light (3 times the minimal erythema dose) for 10 days
Study: 15262693
Drug: MT‐1 (0.16
Approvals — FDA: no, EMA: no, PMDA: no
Description: MT‐1 (0.16 mg/kg per day) with UV‐B radiation (0.25‐0.75 MED) for 10 days
Study: 15262693
Drug: MT‐1 (0.16
Approvals — FDA: no, EMA: no, PMDA: no
Description: MT‐1 (0.16 mg/kg) for 5 days per week for 4 weeks with sunlight
Study: 7807244
Drug: Teaching intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Teaching intervention on pressure ulcer risk, assessment, and treatment
Study: 30832665
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment voucher
Study: 27159290
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal bupivacaine (20 mL Exparel + 20 mL 0.9% saline)
Study: 27159290
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine hydrochloride (20 mL 0.5% bupivacaine HCl + 20 mL 0.9% saline)
Study: 16814935
Drug: Alcohol use
Normalized name: Vorvida Problematic Alcohol Use Support Software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol use during tobacco cessation treatment
Study: 15701778
Drug: Flex-dose group
Normalized name: Ed Flex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flex-dose group (topiramate with adjustable AED cotherapy)
Study: 15701778
Drug: Fixed-dose group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose group (topiramate with fixed AED cotherapy)
Study: 9456212
Drug: Titration search
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titration search procedure
Study: 938161
Drug: C3 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: C3 treatment
Study: 28929695
Drug: Astragali Radix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astragali Radix group 1 (10 g•d⁻¹)
Study: 28929695
Drug: Astragali Radix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astragali Radix group 2 (5 g•d⁻¹)
Study: 28929695
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conventional medical treatment)
Study: 9399755
Drug: RBC 400
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC 400 mg b.i.d., amoxicillin 1 g b.i.d., and clarithromycin 500 mg b.i.d. (RAC)
Study: 9399755
Drug: RBC 400
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC 400 mg b.i.d., metronidazole 250 mg t.i.d., and tetracycline 500 mg t.i.d. (RMT)
Study: 2907080
Drug: Propranolol (PROP)
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol (PROP) 80 mg b.i.d.
Study: 2907080
Drug: Atenolol (ATEN)
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol (ATEN) 100 mg o.d.
Study: 21608219
Drug: Tongxinluo Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongxinluo Capsule (TXL)
Study: 10653873
Drug: Early initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Early initiation of adjuvant chemotherapy within 20 days after surgery (599 patients, 84 with ER-absent tumors)
Study: 10653873
Drug: Conventional initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Conventional initiation of adjuvant chemotherapy 21 to 86 days after surgery (1,189 patients, 142 with ER-absent tumors)
Study: 10653873
Drug: Early initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Early initiation of chemotherapy for ER-expressing tumors (1,562 patients)
Study: 3302842
Drug: Relaxation training
Normalized name: Relax-DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation training (6 weekly sessions of 75 min duration in progressive relaxation)
Study: 30646281
Drug: Standardized program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized program for identification, assessment, and treatment of osteoporosis led by a trained coordinating nurse.
Study: 23990572
Drug: Efavirenz (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efavirenz (600 mg/d) plus standard antituberculosis treatment (rifampicin and isoniazid)
Study: 23990572
Drug: Efavirenz (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efavirenz (600 mg/d) alone
Study: 23990572
Drug: Standard antituberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antituberculosis treatment (rifampicin and isoniazid)
Study: 19166443
Drug: ERN/LRPT 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERN/LRPT 2 g
Study: 12373599
Drug: Analogy of
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analogy of 'a computer will perform the equivalent of tossing a coin to allocate you to one of two methods of treatment'
Study: 2675752
Drug: Norfloxacin, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin, 200 mg orally daily at bedtime
Study: 174244
Drug: DBcAMP administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBcAMP administered intravenously at 10 mg/min for 20 min
Study: 174244
Drug: DBcAMP administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBcAMP administered intravenously at 20 mg/min for 20 min
Study: 7362696
Drug: Oxandrolone (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxandrolone (7.5 mg/day)
Study: 7362696
Drug: PAS-C (6-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAS-C (6-8 g/day)
Study: 7362696
Drug: Colestipol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colestipol (20 g/day)
Study: 25067799
Drug: Baroreflex activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baroreflex activation therapy (BAT) for 6 months
Study: 23069315
Drug: lamivudine and
Normalized name: lamivudine and abacavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: lamivudine and adefovir diprivoxil combination therapy (LA)
Study: 23069315
Drug: lamivudine alone
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: lamivudine alone (L)
Study: 23069315
Drug: lamivudine and
Normalized name: lamivudine and abacavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: lamivudine and adefovir diprivoxil combination therapy (LA) followed by adefovir monotherapy
Study: 19545976
Drug: Risperidone (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (1.5 mg), Perphenazine (8 mg), Ziprasidone (40 mg), Quetiapine (200 mg)
Study: 15138710
Drug: Imatinib 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 200 mg alone
Study: 15138710
Drug: Imatinib 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 200 mg with ketoconazole 400 mg
Study: 9698972
Drug: Placebo drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drug (sham second drug)
Study: 2547464
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate given together and 30 min after diflunisal tablets
Study: 2547464
Drug: Diflunisal (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflunisal (oral administration)
Study: 2547464
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of diflunisal
Study: 1103896
Drug: Verapamil, 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil, 240 mg orally
Study: 31339232
Drug: Autonomic regulation
Normalized name: AUTONOMIC MEDICATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autonomic regulation therapy added to guideline-directed medical therapy (GDMT)
Study: 31339232
Drug: Beta-blocker doses
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker doses in ANTHEM-HF
Study: 31339232
Drug: Beta-blocker doses
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker doses in ANTHEM-HF vs. PARADIGM-HF
Study: 24035673
Drug: Guided internet-delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided internet-delivered cognitive behaviour therapy (ICBT)
Study: 24035673
Drug: Group-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based cognitive behaviour therapy (CBT)
Study: 22187792
Drug: Clonidine 0.5
Normalized name: apraclonidine 0.5 % Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 0.5 ml (75 microg) plus 5 ml 0.25% bupivacaine
Study: 22187792
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml 0.25% bupivacaine plus 0.5 ml of normal saline (NS)
Study: 19001516
Drug: Intralipid (20%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid (20%, 40 ml/h) plus heparin (250 units/h)
Study: 19001516
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (40 ml/h) plus heparin (250 units/h)
Study: 8027497
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate eye drops (Opticrom 2%) used regularly (four times daily)
Study: 8027497
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate eye drops (Opticrom 2%) used as needed (up to four times daily)
Study: 952693
Drug: 1.5% etiodocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% etiodocaine HCl 20 ml with adrenaline 5 mug/ml
Study: 952693
Drug: 0.75% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% bupivacaine HCl 20 ml with adrenaline 5 mug/ml
Study: 9266456
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg BSH/kg body weight administered 2.5‐16 hrs prior to tumor removal
Study: 3546611
Drug: DES-CEF (cyclophosphamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: DES-CEF (cyclophosphamide, 600 mg/m2; DES, 1 mg orally on days 5, 6, and 7; epidoxorubicin, 60 mg/m2; 5-fluorouracil, 600 mg/m2)
Study: 3546611
Drug: CEF (cyclophosphamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEF (cyclophosphamide, 600 mg/m2; epidoxorubicin, 60 mg/m2; 5-fluorouracil, 600 mg/m2)
Study: 30284429
Drug: Medication (conservative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (conservative therapy)
Study: 25381789
Drug: Self-management program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-management program using goal setting based on G-AP
Study: 22795205
Drug: Cognitive‐behavioral therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐behavioral therapy (20 individual sessions)
Study: 17574801
Drug: Standard methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard methadone treatment (control group, n = 49)
Study: 15850918
Drug: High-dose regions
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose regions (V100 >= 90%)
Study: 15850918
Drug: High-dose regions
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose regions (V100 < 90%)
Study: 12825092
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg oral dose of caffeine freebase
Study: 8762218
Drug: enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril 20 mg-hydrochlorothiazide 12.5 mg
Study: 8762218
Drug: enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril 20 mg-nifedipine SL 20 mg x 2
Study: 1342582
Drug: 0.5% timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% timolol maleate with 2% pilocarpine hydrochloride given twice a day
Study: 1342582
Drug: 0.5% timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% timolol with 4% pilocarpine given twice a day
Study: 31612981
Drug: Contraceptive methods
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contraceptive methods (various types including contraceptive pill, withdrawal, breast-feeding)
Study: 31612981
Drug: Age, duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age, duration of marriage, and high monthly income
Study: 24823280
Drug: Metformin-based OAD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin-based OAD
Study: 23659733
Drug: Continued warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued warfarin treatment
Study: 23659733
Drug: Bridging therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bridging therapy with heparin
Study: 18444052
Drug: Lovaas's treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovaas's treatment
Study: 15882879
Drug: Famotidine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine (40 mg per day p.o. for 1 week pre-operatively)
Study: 25267738
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) continued for an additional 6 months (group A1)
Study: 25267738
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) discontinued (group A2)
Study: 19194341
Drug: Drospirenone 2
Normalized name: drospirenone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drospirenone 2 mg/estradiol 1 mg (group 1; n = 15)
Study: 19194341
Drug: Norethisterone acetate
Normalized name: Norethisterone acetate
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norethisterone acetate 0.5 mg/estradiol 1 mg (group 2; n = 15)
Study: 16014067
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose dalteparin (bolus of 40 IU/kg body weight)
Study: 16014067
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose dalteparin
Study: 16014067
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral anticoagulation (phenprocoumon)
Study: 10618886
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (rhGH) at a dose of 0.7 IU/kg per week for 12 months
Study: 7605770
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg hyperbaric 0.75% bupivacaine in 8.25% dextrose
Study: 7605770
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg hyperbaric 0.75% bupivacaine in 8.25% dextrose
Study: 1664824
Drug: Temafloxacin (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temafloxacin (high dose)
Study: 25032141
Drug: No sedative
Normalized name: MedActive Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: No sedative medication (Control)
Study: 20636634
Drug: Valnoctamide (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valnoctamide (600 mg/day increased to 1200 mg after four days)
Study: 18198637
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of propofol (Pro I)
Study: 9871427
Drug: Moxonidine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxonidine treatment after 3, 5, and 11 weeks
Study: 9871427
Drug: Moxonidine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxonidine treatment after 8 weeks
Study: 2694343
Drug: Furazolidone (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furazolidone (7.5 mg/kg/day for 5 days)
Study: 2694343
Drug: Trimethoprim-sulfamethoxazole (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (8 mg/40 mg/kg/day for 5 days)